The importance of viruses in ventilator-associated pneumonia.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
Jul 2023
Historique:
medline: 29 11 2023
pubmed: 30 9 2022
entrez: 29 9 2022
Statut: ppublish

Résumé

Ventilator-associated pneumonia (VAP) remains a challenge. The importance of viruses in VAP is not established. We sought to determine the prevalence of viruses in VAP and the outcomes of viral VAP. Retrospective study of VAP over 3 years. The frequency of a viral process represented the primary endpoint. Clinical outcomes served as secondary endpoints. We identified variables independently associated with a virus and conducted sensitivity analyses to assess the interaction between type of infection and patient characteristics. Tertiary-care referral center. The final cohort consisted of 710 patients and a virus was isolated in 5.1%. None. The most common viruses included: rhinovirus, influenza A, and cytomegalovirus. Baseline characteristics were similar between those with and without viral infections. In logistic regression, immunosuppression (adjusted odds ratio [aOR], 2.97; 95% confidence interval [CI], 1.44-6.14) and stem-cell transplantation (SCT, aOR, 3.58; 95% CI, 1.17-10.99) were independently associated with a virus. The presence of either variable performed poorly as a screening test for a virus. In-hospital (22.4% vs 21.6%; Although infrequent, a range of viruses may cause VAP. Viruses more often complicate SCT and immunosuppression, but one can isolate viruses in immunocompetent subjects. Viral VAP produces severe infection and results in high mortality rates. Clinical features do not differentiate viral from nonviral VAP.

Identifiants

pubmed: 36172891
pii: S0899823X22002239
doi: 10.1017/ice.2022.223
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1137-1142

Auteurs

Andrew F Shorr (AF)

Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center, Washington, DC.

Daniel T Ilges (DT)

Department of Pharmacy, Mayo Clinic, Scottsdale, Arizona.

Scott T Micek (ST)

Department of Pharmacy Practice, University of Health Sciences and Pharmacy, St. Louis, Missouri.

Marin H Kollef (MH)

Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH